Key Points
- Guardant Health CEO Amirali Talasaz sold 210,000 shares on May 20 at an average price of $109.89, generating about $23.1 million in proceeds. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Talasaz also sold 50,000 shares on May 12, continuing a recent pattern of insider selling. After the latest transaction, he still held 1,886,504 shares, worth roughly $207.3 million.
- Guardant Health’s stock has been strong, opening at $118.95 with a 52-week high of $121.01, while analysts remain broadly positive. The company recently beat revenue estimates but missed EPS expectations, and Wall Street’s consensus rating is Moderate Buy with an average price target of $129.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Ian Clark sold 6,876 shares of the business's stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $106.90, for a total value of $735,044.40. Following the sale, the director owned 2,975 shares of the company's stock, valued at $318,027.50. The trade was a 69.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Guardant Health Stock Performance
NASDAQ GH opened at $118.95 on Friday. The firm has a market capitalization of $15.77 billion, a price-to-earnings ratio of -35.09 and a beta of 1.48. Guardant Health, Inc. has a one year low of $36.36 and a one year high of $121.01. The company's 50 day moving average price is $91.15 and its 200 day moving average price is $98.94.
Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. During the same period in the prior year, the company posted ($0.62) EPS. The firm's revenue for the quarter was up 39.4% compared to the same quarter last year. Sell-side analysts forecast that Guardant Health, Inc. will post -2.92 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently weighed in on GH shares. BTIG Research upped their price target on shares of Guardant Health from $140.00 to $145.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Robert W. Baird initiated coverage on Guardant Health in a research note on Tuesday, February 17th. They set an "outperform" rating and a $120.00 price objective on the stock. Stifel Nicolaus upped their target price on Guardant Health from $120.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Citigroup raised their target price on Guardant Health from $135.00 to $150.00 and gave the company a "buy" rating in a report on Friday, February 20th. Finally, Barclays boosted their price target on Guardant Health from $115.00 to $120.00 and gave the stock an "overweight" rating in a research report on Friday, May 8th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $129.00.
Get Our Latest Report on Guardant Health
Institutional Investors Weigh In On Guardant Health
Hedge funds have recently bought and sold shares of the business. Allworth Financial LP increased its holdings in Guardant Health by 19.5% during the 3rd quarter. Allworth Financial LP now owns 844 shares of the company's stock worth $53,000 after purchasing an additional 138 shares during the last quarter. Eastern Bank grew its position in shares of Guardant Health by 6.9% during the fourth quarter. Eastern Bank now owns 2,160 shares of the company's stock worth $221,000 after buying an additional 139 shares in the last quarter. First Pacific Financial grew its position in shares of Guardant Health by 33.1% during the first quarter. First Pacific Financial now owns 559 shares of the company's stock worth $52,000 after buying an additional 139 shares in the last quarter. TD Waterhouse Canada Inc. increased its stake in shares of Guardant Health by 3.2% in the third quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company's stock worth $306,000 after buying an additional 151 shares during the last quarter. Finally, Xponance LLC raised its holdings in Guardant Health by 2.1% in the fourth quarter. Xponance LLC now owns 9,630 shares of the company's stock valued at $984,000 after acquiring an additional 199 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
